MedTrace Logo

Asthmatic Subjects Could Live Without Short Acting beta2 Agonists

NCT03498742 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 86

Last updated 2018-04-17

No results posted yet for this study

Summary

Since 2006 there was a plateau in world wide mortality from asthma. Overreliance in Short Acting Beta2 Agonists (SABA) was associated with increased risk of death from asthma. Long acting beta agonists (LABA) alone was not permitted as treatment for asthma as it was determined by FDA by the "black box". By contrast SABA does not have a "black box", despite similar overuse alerts associated with increased risk of death from asthma. the investigators want to know if exist asthmatic subjects that do use another rescue medication; not SABA, and to compare their features, Asthma Control Test (ACT), and lung function in a outpatient facility.

First consecutive visits at outpatient Pulmonary Section of asthmatic subjects were described. Asthma Control Test (ACT) that was routinely used to assess asthma and spirometry were performed.

Conditions

  • Asthma Chronic

Interventions

OTHER

NO Intervention

Routine clinical data; asthma control test and spirometry

Sponsors & Collaborators

  • Universidad Nacional de Rosario

    lead OTHER

Principal Investigators

  • Luis J Nannini, MD · Universidad Nacional de Rosario

Eligibility

Min Age
16 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-10
Primary Completion
2018-01-16
Completion
2018-01-16

Countries

  • Argentina

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03498742 on ClinicalTrials.gov